Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lenalidomide for the treatment of relapsed and refractory multiple myeloma.
van de Donk NW, Görgün G, Groen RW, Jakubikova J, Mitsiades CS, Hideshima T, Laubach J, Nijhof IS, Raymakers RA, Lokhorst HM, Richardson PG, Anderson KC. van de Donk NW, et al. Among authors: jakubikova j. Cancer Manag Res. 2012;4:253-68. doi: 10.2147/CMAR.S27087. Epub 2012 Aug 14. Cancer Manag Res. 2012. PMID: 22956884 Free PMC article.
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS. McMillin DW, et al. Among authors: jakubikova j. Cancer Res. 2009 Jul 15;69(14):5835-42. doi: 10.1158/0008-5472.CAN-08-4285. Epub 2009 Jul 7. Cancer Res. 2009. PMID: 19584292
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.
McMillin DW, Delmore J, Negri J, Buon L, Jacobs HM, Laubach J, Jakubikova J, Ooi M, Hayden P, Schlossman R, Munshi NC, Lengauer C, Richardson PG, Anderson KC, Mitsiades CS. McMillin DW, et al. Among authors: jakubikova j. Br J Haematol. 2011 Feb;152(4):420-32. doi: 10.1111/j.1365-2141.2010.08427.x. Epub 2011 Jan 11. Br J Haematol. 2011. PMID: 21223249 Free PMC article.
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.
Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS. Jakubikova J, et al. Blood. 2011 Apr 28;117(17):4409-19. doi: 10.1182/blood-2010-02-267344. Epub 2011 Feb 14. Blood. 2011. PMID: 21321360 Free PMC article.
Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma.
Jakubikova J, Cervi D, Ooi M, Kim K, Nahar S, Klippel S, Cholujova D, Leiba M, Daley JF, Delmore J, Negri J, Blotta S, McMillin DW, Hideshima T, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS. Jakubikova J, et al. Haematologica. 2011 Aug;96(8):1170-9. doi: 10.3324/haematol.2010.029363. Epub 2011 Jun 28. Haematologica. 2011. PMID: 21712538 Free PMC article.
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.
Leiba M, Jakubikova J, Klippel S, Mitsiades CS, Hideshima T, Tai YT, Leiba A, Pines M, Richardson PG, Nagler A, Anderson KC. Leiba M, et al. Among authors: jakubikova j. Br J Haematol. 2012 Jun;157(6):718-31. doi: 10.1111/j.1365-2141.2012.09120.x. Epub 2012 Apr 26. Br J Haematol. 2012. PMID: 22533681 Free PMC article. Clinical Trial.
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.
Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC. Blotta S, et al. Among authors: jakubikova j. Blood. 2012 Dec 13;120(25):5002-13. doi: 10.1182/blood-2011-07-368142. Epub 2012 Jul 20. Blood. 2012. PMID: 22821765 Free PMC article.
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Roccaro A, Sacco A, Calimeri T, Cottini F, Jakubikova J, Kong SY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC. Cea M, et al. Among authors: jakubikova j. Blood. 2012 Oct 25;120(17):3519-29. doi: 10.1182/blood-2012-03-416776. Epub 2012 Sep 5. Blood. 2012. PMID: 22955917 Free PMC article.
Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells.
Klippel S, Jakubikova J, Delmore J, Ooi M, McMillin D, Kastritis E, Laubach J, Richardson PG, Anderson KC, Mitsiades CS. Klippel S, et al. Among authors: jakubikova j. Br J Haematol. 2012 Nov;159(3):340-51. doi: 10.1111/j.1365-2141.2012.09253.x. Epub 2012 Sep 13. Br J Haematol. 2012. PMID: 22970818 Free PMC article.
100 results